Full Text View
Tabular View
No Study Results Posted
Related Studies
Transfusions and Nitric Oxide Level in Preterm Infants
This study has been completed.
First Received: November 6, 2008   Last Updated: May 4, 2009   History of Changes
Sponsors and Collaborators: Duke University
Children's Miracle Network
Information provided by: Duke University
ClinicalTrials.gov Identifier: NCT00787124
  Purpose

The purpose of this study is to better understand S-nitrosohemeglobin (SNO-Hb) in transfused blood of extremely preterm infants. The long term goal of the project is to identify variation in the SNO-Hb between packed red blood cell units, and between and among individual preterm infants pre and post-transfusion. Duke investigators are developing methods to replenish SNO-Hb, which, if successful, would improve RBC deformation in addition to providing a vasodilatory stimulation to hypoxic tissue, and lead to a randomized clinical trial testing treated vs. untreated RBC transfusions in extremely premature infants.

AIM 1. Measure the Total Hemoglobin (Hb)-bound nitric oxide (NO), Hb [Fe] NO, SNO-Hb (a calculated value = (total Hb-NO - Hb [Fe] NO) in blood to be transfused in extremely preterm babies, and in samples pre and post- transfusion from the babies.

Hypothesis 1: Measures of NO and SNO-Hb will be low in blood used for transfusion in preterm infants and will be decreased in the post-transfusion samples from the infants compared with the pre-transfusion samples.

AIM 2. Collect clinical data about study participants, including oxygen saturation and measures of perfusion pre and post-transfusion.

Hypothesis 2: Measures of perfusion will be reduced by 20% post-transfusion in extremely preterm infants.


Condition
Prematurity
Anemia
Necrotizing Enterocolitis

MedlinePlus related topics: Anemia Blood Transfusion and Donation
Drug Information available for: Nitric oxide
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Transfusions and Nitric Oxide Level in Preterm Infants

Further study details as provided by Duke University:

Primary Outcome Measures:
  • The primary objective is to measure the Total Hb-bound NO, Hb[Fe]NO, SNO-Hb (a calculated value = (total Hb-NO - Hb[Fe]NO) in blood to be transfused in extremely preterm babies, and in samples pre and post- transfusion from the babies. [ Time Frame: beginning and end of transfusion ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • oxygen saturation and measures of perfusion pre and post-transfusion. [ Time Frame: prior to, during, after transfusion ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

blood specimens for measurement of SNO-Hb. Samples will be discarded after measurement.


Estimated Enrollment: 10
Study Start Date: September 2008
Groups/Cohorts
1
< 28 weeks gestation, < 30 days of age, < 3 previous transfusions
2
< 28 weeks gestation, >=30 days of age, >= 3 previous transfusions

  Eligibility

Ages Eligible for Study:   up to 365 Days
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Infants < 28 weeks gestation at birth undergoing a packed red blood cell transfusion

Criteria

Inclusion Criteria:

  • Infant < 28 weeks gestation at birth
  • Undergoing PRBC transfusion with a volume ≥ 10 cc/kg
  • Availability and willingness of the parent/legally authorized representative to provide written informed consent.

Exclusion Criteria:

  • Any concomitant condition, which in the opinion of the investigator would preclude a patient's participation in the study
  • Previous participation in the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00787124

Locations
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Duke University
Children's Miracle Network
Investigators
Principal Investigator: P Brian Smith, MD MHS Duke University
  More Information

No publications provided

Responsible Party: Duke University Medical Center ( P. Brian Smith, Assistant Professor )
Study ID Numbers: Pro00007939
Study First Received: November 6, 2008
Last Updated: May 4, 2009
ClinicalTrials.gov Identifier: NCT00787124     History of Changes
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Vasodilator Agents
Neurotransmitter Agents
Antioxidants
Gastrointestinal Diseases
Anemia
Necrotizing Enterocolitis
Anti-Asthmatic Agents
Cardiovascular Agents
Intestinal Diseases
Enterocolitis
Nitric Oxide
Digestive System Diseases
Peripheral Nervous System Agents
Enterocolitis, Necrotizing
Gastroenteritis
Bronchodilator Agents

Additional relevant MeSH terms:
Respiratory System Agents
Vasodilator Agents
Neurotransmitter Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Diseases
Physiological Effects of Drugs
Anti-Asthmatic Agents
Cardiovascular Agents
Intestinal Diseases
Protective Agents
Enterocolitis
Pharmacologic Actions
Nitric Oxide
Digestive System Diseases
Autonomic Agents
Therapeutic Uses
Free Radical Scavengers
Endothelium-Dependent Relaxing Factors
Peripheral Nervous System Agents
Enterocolitis, Necrotizing
Gastroenteritis
Bronchodilator Agents

ClinicalTrials.gov processed this record on May 07, 2009